» Articles » PMID: 29967619

Conformational Flexibility in the CD81-Binding Site of the Hepatitis C Virus Glycoprotein E2

Overview
Journal Front Immunol
Date 2018 Jul 4
PMID 29967619
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Numerous antibodies have been described that potently neutralize a broad range of hepatitis C virus (HCV) isolates and the majority of these antibodies target the binding site for the cellular receptor CD81 within the major HCV glycoprotein E2. A detailed understanding of the major antigenic determinants is crucial for the design of an efficient vaccine that elicits high levels of such antibodies. In the past 6 years, structural studies have shed additional light on the way the host's humoral immune system recognizes neutralization epitopes within the HCV glycoproteins. One of the most striking findings from these studies is that the same segments of the E2 polypeptide chain induce antibodies targeting distinct antigen conformations. This was demonstrated by several crystal structures of identical polypeptide segments bound to different antibodies, highlighting an unanticipated intrinsic structural flexibility that allows binding of antibodies with distinct paratope shapes following an "induced-fit" mechanism. This unprecedented flexibility extends to the entire binding site for the cellular receptor CD81, underlining the importance of dynamic analyses to understand (1) the interplay between HCV and the humoral immune system and (2) the relevance of this structural flexibility for virus entry. This review summarizes the current understanding how neutralizing antibodies target structurally flexible epitopes. We focus on differences and common features of the reported structures and discuss the implications of the observed structural flexibility for the viral replication cycle, the full scope of the interplay between the virus and the host immune system and-most importantly-informed vaccine design.

Citing Articles

Characterization and Fluctuations of an Ivermectin Binding Site at the Lipid Raft Interface of the N-Terminal Domain (NTD) of the Spike Protein of SARS-CoV-2 Variants.

Lefebvre M, Chahinian H, La Scola B, Fantini J Viruses. 2025; 16(12.

PMID: 39772146 PMC: 11680242. DOI: 10.3390/v16121836.


Epitope-focused immunogens targeting the hepatitis C virus glycoproteins induce broadly neutralizing antibodies.

Nagarathinam K, Scheck A, Labuhn M, Stroh L, Herold E, Veselkova B Sci Adv. 2024; 10(49):eado2600.

PMID: 39642219 PMC: 11623273. DOI: 10.1126/sciadv.ado2600.


HCV E1 influences the fitness landscape of E2 and may enhance escape from E2-specific antibodies.

Zhang H, Bull R, Quadeer A, McKay M Virus Evol. 2023; 9(2):vead068.

PMID: 38107333 PMC: 10722114. DOI: 10.1093/ve/vead068.


Changes in Soluble Serum CD81 Concentration during an Oral Glucose Tolerance Test in Patients with Diabetes Mellitus and Individuals with Normal Glucose Tolerance.

Kang S, Lee J, Ku B Diagnostics (Basel). 2023; 13(23).

PMID: 38066741 PMC: 10706806. DOI: 10.3390/diagnostics13233500.


Targeting of Tetraspanin CD81 with Monoclonal Antibodies and Small Molecules to Combat Cancers and Viral Diseases.

Bailly C, Thuru X Cancers (Basel). 2023; 15(7).

PMID: 37046846 PMC: 10093296. DOI: 10.3390/cancers15072186.


References
1.
Keck Z, Olson O, Gal-Tanamy M, Xia J, Patel A, Dreux M . A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. J Virol. 2008; 82(12):6067-72. PMC: 2395135. DOI: 10.1128/JVI.00252-08. View

2.
Tarr A, Owsianka A, Timms J, McClure C, Brown R, Hickling T . Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology. 2006; 43(3):592-601. DOI: 10.1002/hep.21088. View

3.
Vieyres G, Dubuisson J, Patel A . Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein. J Gen Virol. 2010; 92(Pt 3):494-506. PMC: 3081231. DOI: 10.1099/vir.0.028092-0. View

4.
Keck Z, Girard-Blanc C, Wang W, Lau P, Zuiani A, Rey F . Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus. J Virol. 2016; 90(6):3112-22. PMC: 4810650. DOI: 10.1128/JVI.02458-15. View

5.
Kong L, Lee D, Kadam R, Liu T, Giang E, Nieusma T . Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. Proc Natl Acad Sci U S A. 2016; 113(45):12768-12773. PMC: 5111675. DOI: 10.1073/pnas.1609780113. View